
This Slide: #23 of 100 |
Slide #23. Mallinckrodt plc — Cadence Pharmaceuticals, Inc.
Acquirer:
Mallinckrodt plc (MNK)
Acquiree:
Cadence Pharmaceuticals, Inc. (CADX)
Details:
Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceuticals company, today announced the successful completion of its acquisition of Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) for total consideration of approximately $1.4 billion. As previously disclosed, Mallinckrodt expects that the acquisition will be immediately accretive to its fiscal year 2014 adjusted diluted earnings per share, and significantly accretive to its fiscal year 2015 adjusted diluted earnings per share.
Mallinckrodt develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare disease in areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy and neonatal respiratory critical care therapies, analgesics and gastrointestinal products. Co. operates its business in two reportable segments: Specialty Brands, which markets branded pharmaceutical products for autoimmune and rare diseases; and Specialty Generics, which includes specialty generic drugs and active pharmaceutical ingredients.
Open the MNK Page at The Online Investor »
Mallinckrodt develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare disease in areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy and neonatal respiratory critical care therapies, analgesics and gastrointestinal products. Co. operates its business in two reportable segments: Specialty Brands, which markets branded pharmaceutical products for autoimmune and rare diseases; and Specialty Generics, which includes specialty generic drugs and active pharmaceutical ingredients.
Open the CADX Page at The Online Investor »
|
|

![]() ![]() Get SEC Filing Alerts Get Dividend Alerts ![]() ![]() |
